PRA has entered into an agreement with Amgen for a series of Phase III studies to develop several biosimilar drugs on a worldwide basis. PRA will serve as the sole provider of CRO services for these studies. Amgen and PRA will work together to execute Phase III studies related to Amgen’s current biosimilar portfolio, as well as the anticipated scope of Amgen’s global biosimilar portfolio. “This agreement reflects and confirms PRA’s commitment to providing full service su...